Amylin scores own goal in Bydureon vs Victoza head-to-head study

Date March 03, 2011

As Amylin Pharmaceuticals must painfully acknowledge today, head-to-head studies are a massive gamble. No matter how carefully designed, an undesirable outcome is always possible.

Expectations were that the company’s new once-weekly diabetes drug Bydureon would prove just as good as Novo Nordisk’s once-daily Victoza at lowering diabetics’ blood sugar levels; some were even hoping it would show superiority. The 25% plunge in the US biotech’s share price this morning indicates that none were anticipating Bydureon to fall short in a head-to-head study. As a result, Novo has been handed a huge gift in the battle for market share among these GLP-1 agonists, while Amylin has scored a grievous own goal.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd